Stocks and Investing
Stocks and Investing
Mon, May 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Fein Maintained (CCCC) at Strong Buy with Decreased Target to $25 on, May 8th, 2023
Andrew Fein of HC Wainwright & Co., Maintained "C4 Therapeutics, Inc." (CCCC) at Strong Buy with Decreased Target from $35 to $25 on, May 8th, 2023.
Andrew has made no other calls on CCCC in the last 4 months.
There are 3 other peers that have a rating on CCCC. Out of the 3 peers that are also analyzing CCCC, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chi Fong of "B of A Securities" Maintained at Hold with Decreased Target to $5 on, Tuesday, March 28th, 2023
These are the ratings of the 2 analyists that currently disagree with Andrew
- Terence Flynn of "Morgan Stanley" Maintained at Sell with Decreased Target to $5 on, Monday, February 27th, 2023
- Eric Joseph of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $5 on, Friday, February 24th, 2023
Contributing Sources